<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947501</url>
  </required_header>
  <id_info>
    <org_study_id>21-228</org_study_id>
    <nct_id>NCT04947501</nct_id>
  </id_info>
  <brief_title>A Study of N9 Chemotherapy in Children With Neuroblastoma</brief_title>
  <official_title>N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether N9 is a safe and effective treatment for&#xD;
      children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that&#xD;
      are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV),&#xD;
      Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine&#xD;
      (CDV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety of the N9 regimen in participants with HR-NB through toxicity assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Adverse events will be graded using Common Toxicity Criteria Version 5.0 developed by the National Cancer Institute of the USA, events of all grades will be tabulated, for non-hematologic effects and hematologic effects on the patients in the safety set. The timing of cycles will also be described to assess any delay due to toxicity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This pilot study of N9 as induction chemotherapy will enroll 15 patients with newly-diagnosed HR-NB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administration of CTV - cycles 1 and 4&#xD;
Days 1 &amp; 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients &gt;10 years old), IV over 6 hrs.&#xD;
Mesna 70 mg/kg (2100 mg/m2/day for patients &gt;10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.&#xD;
******* Administration of CDV - cycle 3 Days 1 &amp; 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients &gt;10 years old), IV over 6 hrs.&#xD;
Mesna 70 mg/kg ((2100 mg/m2/day for patients &gt;10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).&#xD;
Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Administration of CTV - cycles 1 and 4&#xD;
Days 1 &amp; 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients &gt;10 years old), IV over 6 hrs.&#xD;
Mesna 70 mg/kg (2100 mg/m2/day for patients &gt;10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Hycamtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Administration of CTV - cycles 1 and 4&#xD;
Days 1 &amp; 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients &gt;10 years old), IV over 6 hrs.&#xD;
Mesna 70 mg/kg (2100 mg/m2/day for patients &gt;10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Administration of CDV - cycle 3 Days 1 &amp; 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients &gt;10 years old), IV over 6 hrs.&#xD;
Mesna 70 mg/kg ((2100 mg/m2/day for patients &gt;10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).&#xD;
Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Administration of ICE - cycle 2&#xD;
Days 1-5: Ifosfamide 1500 mg/m2/day, IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.&#xD;
Days 1-2: Carboplatin 400 mg/m2/day, IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day, IV over 2 hrs.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Isophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Administration of ICE - cycle 2&#xD;
Days 1-5: Ifosfamide 1500 mg/m2/day, IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.&#xD;
Days 1-2: Carboplatin 400 mg/m2/day, IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day, IV over 2 hrs.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>VePesid</other_name>
    <other_name>Etopophos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administration of ICE - cycle 2&#xD;
Days 1-5: Ifosfamide 1500 mg/m2/day, IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.&#xD;
Days 1-2: Carboplatin 400 mg/m2/day, IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day, IV over 2 hrs.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients &gt;10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.&#xD;
Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.&#xD;
Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients &gt;10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.</description>
    <arm_group_label>Participants with newly-diagnosed HR-Neuroblastoma</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of NB as defined by histopathology (confirmed by the MSK Department of&#xD;
             Pathology), BM metastases plus high urine catecholamine levels, or positivity in MIBG&#xD;
             scan.&#xD;
&#xD;
          -  HR-NB, defined as MYCN-amplified stage 2/3/4/4S at any age and MYCN-nonamplified stage&#xD;
             4 in patients &gt;18 months old.&#xD;
&#xD;
          -  No more than one prior cycle of chemotherapy.&#xD;
&#xD;
          -  Age &gt;1 year to &lt;13 years old.&#xD;
&#xD;
          -  Organ function requirements:&#xD;
&#xD;
        Adequate renal function defined as:&#xD;
&#xD;
        Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m^2 or A serum creatinine based&#xD;
        on age/sex as follows:&#xD;
&#xD;
        Age: 1 to &lt; 2 years Maximum Serum Creatinine (mg/dL): Male, 0.6; Female, 0.6 Age: 2 to &lt; 6&#xD;
        years Maximum Serum Creatinine (mg/dL): Male, 0.8; Female, 0.8 Age: 6 to ≤ 10 years Maximum&#xD;
        Serum Creatinine (mg/dL): Male, 1; Female, 1&#xD;
&#xD;
        The threshold creatinine values in this Table were derived from the Schwartz formula for&#xD;
        estimating GFR utilizing child length and stature data published by the Centers for Disease&#xD;
        Control.&#xD;
&#xD;
        Adequate liver function defined as:&#xD;
&#xD;
        Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and serum alanine&#xD;
        aminotransferase (ALT) &lt; 10 x ULN.&#xD;
&#xD;
        Adequate cardiac function defined as:&#xD;
&#xD;
        Shortening fraction of ≥ 27% by echocardiogram, or Ejection fraction of &gt; 50% by&#xD;
        echocardiogram or radionuclide angiogram.&#xD;
&#xD;
          -  Signed informed consent indicating awareness of the investigational nature of this&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic,&#xD;
             pulmonary, hematologic, or gastrointestinal toxicity ≥ grade 3.&#xD;
&#xD;
          -  Inability to comply with protocol requirements.&#xD;
&#xD;
          -  Pregnancy is not an issue because all patients will be pre-adolescents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Kushner, MD</last_name>
    <phone>1-833-MSK-KIDS</phone>
    <email>kushnerb@MSKCC.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shakeel Modak, MD</last_name>
    <phone>1-833-MSK-KIDS</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Kushner, MD</last_name>
      <phone>833-675-5491</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-NB</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>pediatric cancer</keyword>
  <keyword>21-228</keyword>
  <keyword>Memorial Sloan Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

